The mechanism of the hepatoprotective effect of QS-528 is not known, but it can be assumed that, in a model of metabolic liver damage, it resolves hepatic steatosis through stimulation of the AMP-activated protein kinase (AMPK) signaling pathway as other FFAR1 agonists [31]. This evidence concerns the gene FFAR1 and Hepatic steatosis.